Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model

Transplantation

Volumn 84, Issue 3, 2007, Pages 308-315

  Berman, Dora M ^a,e   Cabrera, Over ^a,b   Kenyon, Norman M ^a   Miller, Joshua ^a   Tam, Susan H ^c   Khandekar, Vrinda S ^c   Picha, Kristen M ^c   Soderman, Avery R ^c   Jordan, Robert E ^c   Bugelski, Peter J ^c   Horninger, Denison ^c   Lark, Michael ^c   Davis, Janet E ^d   Alejandro, Rodolfo ^a   Berggren, Per Olof ^a,b   Zimmerman, Mark ^d   O'Neil, John J ^d   Ricordi, Camillo ^a   Kenyon, Norma S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CENTOCOR INC   (United States)

^d LifeScan   (United States)

^e UNIVERSITY OF MIAMI   (United States)

Author keywords

Coagulation; Graft survival; Islet engraftment; Islet transplantation

Indexed keywords

C PEPTIDE; INSULIN GLARGINE; ISOPHANE INSULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CNTO859; RAPAMYCIN; STEROID; STREPTOZOCIN; TACROLIMUS; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BLOOD GROUP ABO SYSTEM; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; ENGRAFTMENT; FIBRINOLYSIS; FUNCTIONAL STATUS; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATION; MACACA; METABOLIC REGULATION; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; GRAFT SURVIVAL; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MACACA FASCICULARIS; MODELS, BIOLOGICAL; STREPTOZOCIN; THROMBOPLASTIN; TRANSPLANTATION TOLERANCE;

EID: 34547860883     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000275401.80187.1e     Document Type: Article

References (38)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Shapiro AM, Ricordi C, Hering B. Edmonton's islet success has indeed been replicated elsewhere. Lancet 2003; 362: 1242.
3. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710.
4. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 5: 2037.
5. Biarnes M, Montolio M, Nacher V, et al. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002; 51: 66.
6. Dahlback B. Blood coagulation. Lancet 2000; 355: 1627.
7. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A 1990; 87: 6934.
8. Versteeg HH, Peppelenbosch MP, Spek CA. The pleiotropic effects of tissue factor: A possible role for factor VIIa-induced intracellular signalling? Thromb Haemost 2001; 86: 1353.
9. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360: 2039.
10. Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: Possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51: 1779.
11. Nagata M, Mullen Y, Matsuo S, et al. Destruction of islet isografts by severe nonspecific inflammation. Transplant Proc 1990; 22: 855.
12. Kaufman DB, Gores PF, Field MJ, et al. Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass. Diabetes 1994; 43: 778.
13. Kaufman DB, Platt JL, Rabe FL, et al. Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts. J Exp Med 1990; 172: 291.
14. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525.
15. Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J. Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 1985; 40: 424.
16. Johansson U, Olsson A, Gabrielsson S, et al. Inflammatory mediators expressed in human islets of Langerhans: Implications for islet transplantation. Biochem Biophys Res Commun 2003; 308: 474.
17. Bottino R, Balamurugan AN, Tse H, et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 2004; 53: 2559.
18. Grotting JC, Rosai J, Matas AJ, et al. The fate of intraportally transplanted islets in diabetic rats. A morphologic and immunohistochemical study. Am J Pathol 1978; 92: 653.
19. Bennet W, Sundberg B, Groth CG, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48: 1907.
20. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755.
21. Zhang YC, Molano RD, Pileggi A, et al. Adeno-associated virus transduction of islets with interleukin-4 results in impaired metabolic function in syngeneic marginal islet mass transplantation. Transplantation 2002; 74: 1184.
22. Pileggi A, Molano RD, Berney T, et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes 2001; 50: 1983.
23. Arita S, Nagai T, Ochiai M, et al. Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin. Transplantation 2002; 73: 7.
24. Lopez-Talavera JC, Garcia-Ocana A, Sipula I, et al. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: Reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 2004; 145: 467.
25. Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF. VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991; 66: 529.
26. Nehlsen-Cannarella SL, Bohn ML. A direct approach to determine the ABH phenotype of baboons. Immunol Invest 1987; 16: 57.
27. Wijkstrom M, Kirchhof N, Graham M, et al. Cyclosporine toxicity in immunosuppressed streptozotocin-diabetic nonhuman primates. Toxicology 2005; 207: 117.
28. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230.
29. Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48: 1473.
30. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 1999; 96: 8132.
31. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413.
32. Selvaggi G, Fernandez L, Bottino R, et al. Improved baboon pancreatic islet cell isolation. Transplant Proc 1997; 29: 1967.
33. Ricordi C, Gray DW, Hering BJ, et al. Islet isolation assessment in man and large animals. Acta Diabetol Lat 1990; 27: 185.
34. Latif ZA, Noel J, Alejandro R. A simple method of staining fresh and cultured islets. Transplantation 1988; 45: 827.
35. Johnson JE. Methods for studying cell death and viability in primary neuronal cultures. Methods Cell Biol 1995; 46: 243.
36. Idahl LA. A micro perifusion device for pancreatic islets allowing concomitant recordings of intermediate metabolites and insulin release. Anal Biochem 1972; 50: 386.
37. Picha KMT, SH, Khandekar VS, Soderman AR, et al. Effects of lipopolysaccharide on toxicologically important endpoints in cynomolgus macaques. Preclinica 2004; 2: 1.
38. Levi MtC H, Bauer KA, van der Poll T, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114.